Hair Rebonding in Lupus Patients
Patients with systemic lupus erythematosus can undergo hair rebonding procedures, as there is no evidence linking chemical hair treatments to disease flares or worsening outcomes. However, this should be approached with consideration of the patient's current disease activity, scalp involvement, and hair condition.
Evidence Base
The only direct evidence examining hair treatments in SLE comes from a large case-control study that found no significant association between chemical hair treatments (including permanent coloring, non-permanent coloring, bleach, or lowlights) and the development or worsening of SLE 1. Importantly, neither the use of these treatments nor their duration showed any significant differences between SLE patients and healthy controls.
Clinical Considerations Before Proceeding
Assess Current Disease Status
Active scalp involvement: If the patient has active discoid lupus lesions, cutaneous lupus, or significant scalp inflammation, delay the procedure until the skin is stable. Chemical treatments on inflamed or damaged skin can cause additional irritation and potentially worsen local disease 2.
Hair fragility: Lupus patients, particularly those on immunosuppressive therapy or with active disease, may have fragile hair that is more prone to breakage. The chemical process of rebonding can further stress already compromised hair.
Photoprotection Remains Essential
While hair rebonding itself is not contraindicated, remember that photoprotection is a cornerstone of lupus management 3. Patients should continue strict sun protection measures regardless of cosmetic hair procedures, as UV exposure can trigger disease flares.
Practical Recommendations
Proceed with hair rebonding if:
- Disease is in remission or low disease activity
- No active scalp lesions or inflammation
- Hair quality is reasonable (not severely damaged or thinning)
- Patient is on stable maintenance therapy
Delay or avoid if:
- Active discoid lupus on scalp
- Significant alopecia or hair fragility
- Recent disease flare or medication changes
- Scalp photosensitivity or active rashes
Important Caveats
The absence of evidence showing harm does not mean these procedures are risk-free in all situations. Individual scalp sensitivity, concurrent medications (particularly those causing photosensitivity), and the specific chemicals used in rebonding products may create unique risks. Perform a patch test before full application to assess for individual hypersensitivity reactions, which may be more common in patients with autoimmune conditions.
Ensure the patient understands that while the chemical treatment itself is not contraindicated, maintaining overall disease control with hydroxychloroquine (at ≤5 mg/kg/day) 4, 5, minimizing glucocorticoids, and adhering to photoprotection measures remain the priorities for preventing disease flares and maintaining quality of life.